Pfizer Says COVID-19 Trial Ends With 95% Efficacy, Will Seek Authorization

The drugmaker said the efficacy of the vaccine developed with German partner BioNTech was consistent across age and ethnicity demographics.The drugmaker said the efficacy of the vaccine developed with German partner BioNTech was consistent across age and ethnicity demographics.Read More